Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra-Peptide in healthy volunteers - LipOra trial

niversität Heidelberg vertreten durch das Universitätsklinikum0 个研究点目标入组 95 人开始时间: 2023年7月14日最近更新: 2024年8月19日

适应症

试验速览

阶段: 1 期
状态: 尚未招募
发起方
入组人数: 95

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: N/a: Single Arm Study
盲法: Open (masking not used)

入排标准

年龄范围: 18 Years 至 50 Years（—）
性别: All

入选标准

•Men and women of childbearing potential (WOCBP) who are willing to use a highly effective method of contraception during the treatment and 7 d after the last administration of the investigational medicinal product (IMP), or women of no childbearing potential (WNCBP) [defined as women who underwent surgical sterilization (hysterectomy, bilateral oophorectomy or bilateral tubal ligation) or cessation of menses for 12 or more consecutive months and a follicle stimulating hormone (FSH) test with FSH levels 40 mIU/ml], or individuals who are convincingly sexually abstinent,
•- An understanding, ability, and willingness to fully comply with study interventions and restrictions,
•- Ability to provide written, personally signed and dated informed consent to participate in the study, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any study-related interventions.
•- Body mass index < 30 kg/m2,
•- Willingness to follow the pertinent guidelines for prevention of spreading SARS-CoV2 based on SOPs of the hospital administration of the trial site. This may include a SARS-CoV2 testing and proof of vaccination. These rules may change during the course of the trial.

排除标准

•At the time of SCR
•1. Clinically significant or relevant abnormalities in the medical history, physical examination, and laboratory evaluation as assessed by the investigator,
•2. Ongoing or past history of physical or psychiatric illness judged by the investigator as clinically relevant,
•3. Pregnancy or breast feeding,
•4. Any acute or chronic illness or clinically relevant finding known or expected to modify absorption, distribution, metabolism, or excretion of OTT,
•5. Any known history of severe allergic or anaphylactic reactions to drugs or food or any other clinically significant allergies,
•6. Any known allergies to OTT or further ingredients of the trial drugs,
•7. Clinically relevant findings in any of the following investigations at SCR. Minor deviations of laboratory values from the normal range may be accepted if, in the opinion of the investigator, they have no clinical significance for this trial,
•a) Hemoglobin (Hb) < 12 g/dl (males) or < 11 g/dl (females),
•b) Creatinine clearance < 60 ml/min (Cockcroft-Gault),
•c) Total bilirubin > 1.2 x upper limit of normal (ULN), in case of suspected Gilbert’s disease: total bilirubin = 3 x ULN is acceptable,
•d) Alanine aminotransferase (ALT) > 1.1 x ULN,
•e) Aspartate aminotransferase (AST) > 1.2 x ULN,
•f) Thyroid-stimulating hormone (TSH) not within normal limits,
•g) Creatine kinase (CK) not within normal limits (volunteers with CK elevations between = 3 x ULN may be included if troponin T is negative),
•8. A positive human immunodeficiency virus (HIV) or hepatitis C (HCV) antibody screen, or positive result for Hepatitis B surface antigen (HBsAg),
•9. A positive result in the drug screening test at SCR,
•10. Any intake of substances (prescription medication, over-the-counter medicine, or herbal preparations with active ingredients) known to inhibit drug metabolizing enzymes or transport enzymes within a period of less than 5 times the respective elimination half-life (t1/2) with regard to the expected date of first dose of IMP (except hormonal contraception, iodine, and levothyroxine),
•11. Any intake of substances (prescription medication, over-the-counter medicine, or herbal preparations with active ingredients) known to induce drug metabolizing enzymes or transport enzymes within a period of 14 d with regard to the expected date of first dose of IMP,
•12. Use of another IMP within 30 d prior to receiving the first dose of IMP or active enrolment in another drug or vaccine clinical trial,
•13. History of immunization within 14 d prior to expected dosing, including SARS-CoV2 vaccinations, and/ or plans to get vaccinated during the observation time.
•At day 1, prior to dosing:
•14. Any relevant intercurrent illness since SCR,
•15. Any intake of substances (prescription medication, over-the-counter medicine, or herbal preparations with active ingredients) known to inhibit drug metabolizing enzymes or transport enzymes within a period of less than 5 times the respective elimination half-life (t1/2) with regard to the expected date of first dose of IMP (except hormonal contraception, iodine, and levothyroxine),
•16. Any intake of substances (prescription medication, over-the-counter medicine, or herbal preparations with active ingredients) known to induce drug metabolizing enzymes or transport enzymes within a period of 14 d with regard to the expected date of first dose of IMP, and
•17. Ingestion of a meal within the last 10 h (non-fasting state).

研究者

发起方

niversität Heidelberg vertreten durch das Universitätsklinikum

相似试验

已完成

不适用

A phase 1 first-in-human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG232 in adult subjects with advanced solid tumors or multiple myelomasolide tumorentumor in the organs

NL-OMON44939Amgen42

已完成

1 期

First-In-Human Pilot Study to Demonstrate the Safety and the Performance of the Cardiac Microcurrent Therapy System (CMIC System)I50.9Heart failure, unspecified

DRKS00015708Berlin Heals GmbH10

已完成

1 期

A phase I clinical trial evaluating the safety of allogeneic Adipose Tissue-derived multilineage progenitor cells-transplantation therapy in severe familial hypercholesterolemia patientsSevere familial hypercholesterolemia (mainly homozygotes) undergoing LDL-apheresis

JPRN-UMIN000020591Osaka University Graduate School of Medicine4

已完成

1 期

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Multiple MyelomaRelapsed or Refractory Acute Myeloid Leukemia

JPRN-jRCT2080224749Amgen K.K.175

暂停

1 期

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid Leukemia (AML)

JPRN-jRCT2031210152ocal Contact200